Familial pheochromocytomas and paragangliomas associated with mutations of the succinate dehydrogenase genes

References

• DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics: World Health Organization classification of tumours of endocrine organs. Oxford University Press, Oxford, UK (2004).
   Google Scholar
• Pacak K, Keiser H, Eisenhofer G. Pheochromocytoma. In: Textbook of Endocrinology. Elsevier Saunders, Inc., Philadelphia, PA, 2501–2534 (2005).
   Google Scholar
• Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet366(9486), 665–675 (2005).
   PubMed Web of Science ®Google Scholar
• Erickson D, Kudva YC, Ebersold MJ et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J. Clin. Endocrinol. Metab.86(11), 5210–5216 (2001).
   PubMed Web of Science ®Google Scholar
• Astuti D, Latif F, Dallol A et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet.69(1), 49–54 (2001).
   PubMed Web of Science ®Google Scholar
• Baysal BE, Ferrell RE, Willett-Brozick JE et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science287(5454), 848–851 (2000).
   PubMed Web of Science ®Google Scholar
• Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet.26(3), 268–270 (2000).
   PubMed Web of Science ®Google Scholar
• Fokkema IF, den Dunnen JT, Taschner PE. LOVD: easy creation of a locus-specific sequence variation database using an “LSDB-in-a-box” approach. Hum. Mutat.26(2), 63–68 (2005).
   Google Scholar
• Dahia PL, Hao K, Rogus J et al. Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res.65(21), 9651–9658 (2005).
   PubMed Web of Science ®Google Scholar
• Amar L, Bertherat J, Baudin E et al. Genetic testing in pheochromocytoma or functional paraganglioma. J. Clin. Oncol.23(34), 8812–8818 (2005).
   PubMed Web of Science ®Google Scholar
• Benn DE, Gimenez-Roqueplo AP, Reilly JR et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J. Clin. Endocrinol. Metab.91(3), 827–836 (2006).
   PubMed Web of Science ®Google Scholar
• Neumann HP, Pawlu C, Peczkowska M et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA292(8), 943–951 (2004).
   PubMed Web of Science ®Google Scholar
• Schiavi F, Boedeker CC, Bausch B et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA294(16), 2057–2063 (2005).
   PubMed Web of Science ®Google Scholar
• Young AL, Baysal BE, Deb A, Young WF Jr. Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. J. Clin. Endocrinol. Metab.87(9), 4101–4105 (2002).
   Web of Science ®Google Scholar
• Pham TH, Moir C, Thompson GB et al. Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center. Pediatrics118(3), 1109–1117 (2006).
   Web of Science ®Google Scholar
• Timmers HJ, Kozupa K, Eisenhofer G et al. Clinical presentations, biochemical phenotypes, and genotype–phenotype correlations in patients with SDHB-associated pheochromocytomas and paragangliomas. J. Clin. Endocrinol. Metab.92(3), 779–786 (2007).
   Google Scholar
• Brouwers FM, Eisenhofer G, Tao JJ et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J. Clin. Endocrinol. Metab.91(11), 4505–4509 (2006).
   PubMed Web of Science ®Google Scholar
• Timmers HJ, Kozupa K, Chen CC et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. JCO (2007) (In Press).
   Google Scholar
• Scheffler IE. Molecular genetics of succinate:quinone oxidoreductase in eukaryotes. Prog. Nucleic Acid Res. Mol. Biol.60, 267–315 (1998).
   PubMed Web of Science ®Google Scholar
• Bourgeron T, Rustin P, Chretien D et al. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nat. Genet.11(2), 144–149 (1995).
   PubMed Web of Science ®Google Scholar
• Birch-Machin MA, Taylor RW, Cochran B, Ackrell BA, Turnbull DM. Late-onset optic atrophy, ataxia, and myopathy associated with a mutation of a complex II gene. Ann. Neurol.48(3), 330–335 (2000).
   Google Scholar
• Gimenez-Roqueplo AP, Favier J, Rustin P et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res.63(17), 5615–5621 (2003).
   PubMed Web of Science ®Google Scholar
• Gimenez-Roqueplo AP, Favier J, Rustin P et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am. J. Hum. Genet.69(6), 1186–1197 (2001).
   PubMed Web of Science ®Google Scholar
• Gimenez-Roqueplo AP, Favier J, Rustin P et al. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J. Clin. Endocrinol. Metab.87(10), 4771–4774 (2002).
   PubMedGoogle Scholar
• Lee S, Nakamura E, Yang H et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell8(2), 155–167 (2005).
   PubMed Web of Science ®Google Scholar
• Selak MA, Armour SM, MacKenzie ED et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell7(1), 77–85 (2005).
   PubMed Web of Science ®Google Scholar
• Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer5(11), 857–866 (2005).
   PubMed Web of Science ®Google Scholar
• Elston MS, Benn D, Robinson BG, Conaglen JV. An apparently sporadic paraganglioma with an SDHB gene germline mutation presenting at age 68 years. Intern. Med. J.36(2), 129–131 (2006).
   Google Scholar
• Linnoila RI, Keiser HR, Steinberg SM, Lack EE. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum. Pathol.21(11), 1168–1180 (1990).
   PubMed Web of Science ®Google Scholar
• Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension29(5), 1133–1139 (1997).
   PubMed Web of Science ®Google Scholar
• Amar L, Servais A, Gimenez-Roqueplo AP et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J. Clin. Endocrinol. Metab.90(4), 2110–2116 (2005).
   PubMed Web of Science ®Google Scholar
• Goldstein RE, O’Neill JA Jr, Holcomb GW III et al. Clinical experience over 48 years with pheochromocytoma. Ann. Surg.229(6), 755–764; discussion 764–756 (1999).
   Google Scholar
• Khorram-Manesh A, Ahlman H, Nilsson O et al. Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J. Intern. Med.258(1), 55–66 (2005).
   Google Scholar
• Vanharanta S, Buchta M, McWhinney SR et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet.74(1), 153–159 (2004).
   PubMed Web of Science ®Google Scholar
• Cascon A, Montero-Conde C, Ruiz-Llorente S et al. Gross SDHB deletions in patients with paraganglioma detected by multiplex PCR: a possible hot spot? Genes Chromosomes Cancer45(3), 213–219 (2006).
   Google Scholar
• McWhinney SR, Pilarski RT, Forrester SR et al. Large germline deletions of mitochondrial complex II subunits SDHB and SDHD in hereditary paraganglioma. J. Clin. Endocrinol. Metab.89(11), 5694–5699 (2004).
   PubMedGoogle Scholar
• Benn DE, Robinson BG. Genetic basis of phaeochromocytoma and paraganglioma. Best Pract. Res. Clin. Endocrinol. Metab.20(3), 435–450 (2006).
   Google Scholar
• Ogawa K, Shiga K, Saijo S et al. A novel G106D alteration of the SDHD gene in a pedigree with familial paraganglioma. Am. J. Med. Genet. A140(22), 2441–2446 (2006).
   Google Scholar
• Havekes B, Corssmit EP, Jansen JC et al. Malignant paragangliomas associated with mutations in the succinate dehydrogenase D gene. J. Clin. Endocrinol. Metab. (2007).
   Google Scholar
• Astrom K, Cohen JE, Willett-Brozick JE, Aston CE, Baysal BE. Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect. Hum. Genet.113(3), 228–237 (2003).
   PubMedGoogle Scholar
• Bayley JP, van Minderhout I, Weiss MM et al. Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma. BMC Med. Genet.7, 1 (2006).
   PubMed Web of Science ®Google Scholar
• Bauters C, Vantyghem MC, Leteurtre E et al. Hereditary phaeochromocytomas and paragangliomas: a study of five susceptibility genes. J. Med. Genet.40(6), E75 (2003).
   PubMed Web of Science ®Google Scholar
• Niemann S, Muller U, Engelhardt D, Lohse P. Autosomal dominant malignant and catecholamine-producing paraganglioma caused by a splice donor site mutation in SDHC. Hum. Genet.113(1), 92–94 (2003).
   PubMed Web of Science ®Google Scholar
• Baysal BE, Willett-Brozick JE, Filho PA et al. An Alu-mediated partial SDHC deletion causes familial and sporadic paraganglioma. J. Med. Genet.41(9), 703–709 (2004).
   PubMed Web of Science ®Google Scholar
• Neumann HP, Bausch B, McWhinney SR et al. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med.346(19), 1459–1466 (2002).
   PubMed Web of Science ®Google Scholar
• Gimenez-Roqueplo AP, Lehnert H, Mannelli M et al. Phaeochromocytoma, new genes and screening strategies. Clin. Endocrinol. (Oxf.)65(6), 699–705 (2006).
   PubMedGoogle Scholar
• Lenders JW, Pacak K, Walther MM et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA287(11), 1427–1434 (2002).
   PubMed Web of Science ®Google Scholar
• Eisenhofer G, Lenders JW, Goldstein DS et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin. Chem.51(4), 735–744 (2005).
   PubMed Web of Science ®Google Scholar
• Bonnet S, Durand X, Baton O et al. Malignant hereditary paraganglioma: problems raised by non-functional forms management. Ann. Chir.131(10), 626–630 (2006).
   Google Scholar
• Eisenhofer G, Goldstein DS, Sullivan P et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J. Clin. Endocrinol. Metab.90(4), 2068–2075 (2005).
   PubMed Web of Science ®Google Scholar
• Maurea S, Cuocolo A, Reynolds JC, Neumann RD, Salvatore M. Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison. QJ Nucl. Med.40(4), 365–371 (1996).
   Google Scholar
• Ilias I, Shulkin B, Pacak K. New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends Endocrinol. Metab.16(2), 66–72 (2005).
   Google Scholar
• Belhocine T, Spaepen K, Dusart M et al. 18FDG PET in oncology: the best and the worst (Review). Int. J. Oncol.28(5), 1249–1261 (2006).
   Google Scholar
• Kwekkeboom DJ, van Urk H, Pauw BK et al. Octreotide scintigraphy for the detection of paragangliomas. J. Nucl. Med.34(6), 873–878 (1993).
   Web of Science ®Google Scholar
• Janetschek G, Finkenstedt G, Gasser R et al. Laparoscopic surgery for pheochromocytoma: adrenalectomy, partial resection, excision of paragangliomas. J. Urol.160(2), 330–334 (1998).
   PubMed Web of Science ®Google Scholar
• Niemann U, Hiller W, Behrend M. 25 years experience of the surgical treatment of phaeochromocytoma. Eur. J. Surg.168(12), 716–719 (2002).
   Google Scholar
• Stenstrom G, Ernest I, Tisell LE. Long-term results in 64 patients operated upon for pheochromocytoma. Acta Med. Scand.223(4), 345–352 (1988).
   PubMed Web of Science ®Google Scholar
• Fitzgerald PA, Goldsby RE, Huberty JP et al. Malignant pheochromocytomas and paragangliomas: a Phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann. NY Acad. Sci.1073, 465–490 (2006).
   PubMed Web of Science ®Google Scholar
• Averbuch SD, Steakley CS, Young RC et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann. Intern. Med.109(4), 267–273 (1988).
   PubMed Web of Science ®Google Scholar
• Eisenhofer G, Bornstein SR, Brouwers FM et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr. Relat. Cancer11(3), 423–436 (2004).
   PubMed Web of Science ®Google Scholar
• Young WF Jr, Abboud AL. Editorial: paraganglioma – all in the family. J. Clin. Endocrinol. Metab.91(3), 790–792 (2006).
   PubMed Web of Science ®Google Scholar
• Pacak K, Eisenhofer G, Carrasquillo JA et al. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension38(1), 6–8 (2001).
   PubMed Web of Science ®Google Scholar